The stock of Vericel Corp (NASDAQ:VCEL) is a huge mover today! About 629,939 shares traded hands or 178.44% up from the average. Vericel Corp (NASDAQ:VCEL) has risen 36.36% since March 7, 2016 and is uptrending. It has outperformed by 28.77% the S&P500.
The move comes after 6 months positive chart setup for the $71.21M company. It was reported on Oct, 10 by Barchart.com. We have $6.54 PT which if reached, will make NASDAQ:VCEL worth $82.60 million more.
Analysts await Vericel Corp (NASDAQ:VCEL) to report earnings on November, 11.
Vericel Corp (NASDAQ:VCEL) Ratings Coverage
Out of 2 analysts covering Vericel (NASDAQ:VCEL), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. Vericel has been the topic of 2 analyst reports since March 11, 2016 according to StockzIntelligence Inc. Bank of America downgraded the shares of VCEL in a report on Tuesday, April 5 to “Neutral” rating. The stock has “Buy” rating given by Needham on Friday, March 11.
According to Zacks Investment Research, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.”
More important recent Vericel Corp (NASDAQ:VCEL) news were published by: Marketwatch.com which released: “Vericel Corp. NASDAQ: VCEL” on November 28, 2014, also Quotes.Wsj.com published article titled: “News Vericel Corp.VCEL”, Globenewswire.com published: “Aastrom Biosciences Announces Plans to Change Name to Vericel Corporation and …” on October 09, 2014. More interesting news about Vericel Corp (NASDAQ:VCEL) was released by: Seekingalpha.com and their article: “Why Vericel Shares Will Double In 2015 (VCEL)” with publication date: February 06, 2015.
VCEL Company Profile
Vericel Corporation (Vericel), formerly Aastrom Biosciences, Inc., incorporated on March 24, 1989, is a commercial-stage biopharmaceutical firm dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Firm operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Vericel markets two autologous cell therapy products in the United States: Carticel (autologous cultured chondrocytes), an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns approximately 30% of total body surface area (TBSA).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.